Advertisement

Effect of Abciximab on Clinical and Angiographic Restenosis in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes

      The ISAR-REACT 2 trial was designed to assess the effect of abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after a 600-mg loading dose of clopidogrel. The aim of the present study was to investigate the impact of abciximab on clinical and angiographic restenosis after coronary stenting in patients with acute coronary syndromes. The angiographic substudy included 1,544 patients from the ISAR-REACT 2 trial randomly assigned to abciximab (771 patients) or placebo (773 patients). All patients were scheduled for routine angiographic follow-up at 6 to 8 months after intervention. The primary end point was incidence of angiographic in-segment binary restenosis. The secondary end point was 1-year incidence of target-lesion revascularization. Binary restenosis was observed in 21.9% of patients in the abciximab group and 24.5% of patients in the placebo group (p = 0.29). Percentages of in-stent (29 ± 22% vs 33 ± 24%; p = 0.02) and in-segment (35 ± 20% vs 38 ± 21%; p = 0.04) diameter stenoses were significantly lower in the abciximab group than the placebo group. There was a strong trend toward lower 1-year incidence of target-lesion revascularization in patients treated with abciximab than in patients treated with placebo (13.6% vs 16.8%; p = 0.08). In conclusion, in patients with non–ST-segment elevation acute coronary syndromes undergoing early percutaneous coronary intervention with stenting after a 600-mg loading dose of clopidogrel, abciximab therapy may have a slight positive impact on the prevention of restenosis.
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cannon C.P.
        • Weintraub W.S.
        • Demopoulos L.A.
        • Vicari R.
        • Frey M.J.
        • Lakkis N.
        • Neumann F.J.
        • Robertson D.H.
        • DeLucca P.T.
        • DiBattiste P.M.
        • Gibson C.M.
        • Braunwald E.
        Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
        N Engl J Med. 2001; 344: 1879-1887
        • FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators
        Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study.
        Lancet. 1999; 354: 708-715
        • Schömig A.
        • Neumann F.J.
        • Kastrati A.
        • Schuhlen H.
        • Blasini R.
        • Hadamitzky M.
        • Walter H.
        • Zitzmann-Roth E.M.
        • Richardt G.
        • Alt E.
        • Schmitt C.
        • Ulm K.
        A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.
        N Engl J Med. 1996; 334: 1084-1089
        • Steinhubl S.R.
        • Berger P.B.
        • Mann III, J.T.
        • Fry E.T.
        • DeLago A.
        • Wilmer C.
        • Topol E.J.
        Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
        JAMA. 2002; 288: 2411-2420
        • Kastrati A.
        • Mehilli J.
        • Schuhlen H.
        • Dirschinger J.
        • Dotzer F.
        • ten Berg J.M.
        • Neumann F.J.
        • Bollwein H.
        • Volmer C.
        • Gawaz M.
        • Berger P.B.
        • Schömig A.
        A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
        N Engl J Med. 2004; 350: 232-238
        • Lincoff A.M.
        • Califf R.M.
        • Moliterno D.J.
        • Ellis S.G.
        • Ducas J.
        • Kramer J.H.
        • Kleiman N.S.
        • Cohen E.A.
        • Booth J.E.
        • Sapp S.K.
        • Cabot C.F.
        • Topol E.J.
        Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors.
        N Engl J Med. 1999; 341: 319-327
        • Marso S.P.
        • Lincoff A.M.
        • Ellis S.G.
        • Bhatt D.L.
        • Tanguay J.F.
        • Kleiman N.S.
        • Hammoud T.
        • Booth J.E.
        • Sapp S.K.
        • Topol E.J.
        Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
        Circulation. 1999; 100: 2477-2484
        • Stone G.W.
        • Grines C.L.
        • Cox D.A.
        • Garcia E.
        • Tcheng J.E.
        • Griffin J.J.
        • Guagliumi G.
        • Stuckey T.
        • Turco M.
        • Carroll J.D.
        • Rutherford B.D.
        • Lansky A.J.
        Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
        N Engl J Med. 2002; 346: 957-966
        • Kastrati A.
        • Mehilli J.
        • Neumann F.J.
        • Dotzer F.
        • ten Berg J.
        • Bollwein H.
        • Graf I.
        • Ibrahim M.
        • Pache J.
        • Seyfarth M.
        • et al.
        Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
        JAMA. 2006; 295: 1531-1538
        • Schühlen H.
        • Kastrati A.
        • Mehilli J.
        • Hausleiter J.
        • Dirschinger J.
        • Dotzer F.
        • Bollwein H.
        • Schömig A.
        Abciximab and angiographic restenosis after coronary stent placement.
        Am Heart J. 2006; 151: 1248-1254
        • Ellis S.G.
        • Vandormael M.G.
        • Cowley M.J.
        • DiSciascio G.
        • Deligonul U.
        • Topol E.J.
        • Bulle T.M.
        Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease.
        Circulation. 1990; 82: 1193-1202
        • The EPILOG Investigators
        Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
        N Engl J Med. 1997; 336: 1689-1696
        • Hausleiter J.
        • Kastrati A.
        • Mehilli J.
        • Schuhlen H.
        • Pache J.
        • Dotzer F.
        • Glatthor C.
        • Siebert S.
        • Dirschinger J.
        • Schömig A.
        A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries.
        J Intern Med. 2004; 256: 388-397
        • Mehilli J.
        • Kastrati A.
        • Schuhlen H.
        • Dibra A.
        • Dotzer F.
        • von Beckerath N.
        • Bollwein H.
        • Pache J.
        • Dirschinger J.
        • Berger P.P.
        • Schömig A.
        Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
        Circulation. 2004; 110: 3627-3635
        • Montalescot G.
        • Barragan P.
        • Wittenberg O.
        • Ecollan P.
        • Elhadad S.
        • Villain P.
        • Boulenc J.M.
        • Morice M.C.
        • Maillard L.
        • Pansieri M.
        • Choussat R.
        • Pinton P.
        Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
        N Engl J Med. 2001; 344: 1895-1903
        • Tcheng J.E.
        • Kandzari D.E.
        • Grines C.L.
        • Cox D.A.
        • Effron M.B.
        • Garcia E.
        • Griffin J.J.
        • Guagliumi G.
        • Stuckey T.
        • Turco M.
        • et al.
        • CADILLAC Investigators
        Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
        Circulation. 2003; 108: 1316-1323
        • Le Breton H.
        • Plow E.F.
        • Topol E.J.
        Role of platelets in restenosis after percutaneous coronary revascularization.
        J Am Coll Cardiol. 1996; 28: 1643-1651
        • Schwartz R.S.
        • Holmes Jr, D.R.
        • Topol E.J.
        The restenosis paradigm revisited: an alternative proposal for cellular mechanisms.
        J Am Coll Cardiol. 1992; 20: 1284-1293
        • Romagnoli E.
        • Burzotta F.
        • Trani C.
        • Biondi-Zoccai G.G.
        • Giannico F.
        • Crea F.
        Rationale for intracoronary administration of abciximab.
        J Thromb Thrombolysis. 2007; 23: 57-63
        • Tam S.H.
        • Sassoli P.M.
        • Jordan R.E.
        • Nakada M.T.
        Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins.
        Circulation. 1998; 98: 1085-1091
        • Nurden A.T.
        • Poujol C.
        • Durrieu-Jais C.
        • Nurden P.
        Platelet glycoprotein IIb/IIIa inhibitors: basic and clinical aspects.
        Arterioscler Thromb Vasc Biol. 1999; 19: 2835-2840
        • Stouffer G.A.
        • Hu Z.
        • Sajid M.
        • Li H.
        • Jin G.
        • Nakada M.T.
        • Hanson S.R.
        • Runge M.S.
        Beta3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells.
        Circulation. 1998; 97: 907-915
        • Morice M.C.
        • Serruys P.W.
        • Sousa J.E.
        • Fajadet J.
        • Ban Hayashi E.
        • Perin M.
        • Colombo A.
        • Schuler G.
        • Barragan P.
        • Guagliumi G.
        • Molnar F.
        • Falotico R.
        A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.
        N Engl J Med. 2002; 346: 1773-1780
        • Colombo A.
        • Drzewiecki J.
        • Banning A.
        • Grube E.
        • Hauptmann K.
        • Silber S.
        • Dudek D.
        • Fort S.
        • Schiele F.
        • Zmudka K.
        • Guagliumi G.
        • Russell M.E.
        Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions.
        Circulation. 2003; 108: 788-794
        • Kastrati A.
        • Mehilli J.
        • Pache J.
        • Kaiser C.
        • Valgimigli M.
        • Kelbaek H.
        • Menichelli M.
        • Sabate M.
        • Suttorp M.J.
        • Baumgart D.
        • et al.
        Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.
        N Engl J Med. 2007; 356: 1030-1039
        • Lansky A.J.
        • Costa R.A.
        • Mintz G.S.
        • Tsuchiya Y.
        • Midei M.
        • Cox D.A.
        • O'Shaughnessy C.
        • Applegate R.A.
        • Cannon L.A.
        • Mooney M.
        • et al.
        Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial.
        Circulation. 2004; 109: 1948-1954
        • Teirstein P.S.
        • Kao J.
        • Watkins M.
        • Tannenbaum M.A.
        • Laufer N.
        • Chang M.
        • Mehran R.
        • Dangas G.
        • Russell M.E.
        • Ellis S.G.
        • Stone G.W.
        Impact of platelet glycoprotein IIb/IIIa inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy).
        Am J Cardiol. 2005; 96: 500-505
        • Ndrepepa G.
        • Kastrati A.
        • Mehilli J.
        • Neumann F.J.
        • ten Berg J.
        • Bruskina O.
        • Dotzer F.
        • Seyfarth M.
        • Pache J.
        • Dirschinger J.
        • et al.
        Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions.
        Circulation. 2006; 114: 2040-2046
        • Mehilli J.
        • Ndrepepa G.
        • Kastrati A.
        • Neumann F.J.
        • ten Berg J.
        • Bruskina O.
        • Dotzer F.
        • Seyfarth M.
        • Pache J.
        • Kufner S.
        • et al.
        Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial.
        Am Heart J. 2007; 154 (e1–e7): 158